The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zabaznyĭ N.P.

Moskovskaia gorodskaia onkologicheskaia bol'nitsa #62

Shveikin A.O.

Moscow City Cancer Hospital No. 62 of Moscow Healthcare Department, Moscow, Russia

Grinevich V.N.

GBUZ "Moskovskaia gorodskaia onkologicheskaia bol'nitsa #62"

Demidova I.A.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN", Moskva;
FGBU "Moskovskiĭ NII pediatrii i detskoĭ khirurgii Minzdrava Rossii", Moskva;
Moskovskiĭ gorodskoĭ psikhologo-pedagogicheskiĭ universitet, Moskva

Current approaches to the diagnosis and treatment of gastrointestinal stromal tumors

Authors:

Zabaznyĭ N.P., Shveikin A.O., Grinevich V.N., Demidova I.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(3): 82‑87

Views: 1864

Downloaded: 6

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Zabaznyĭ NP, Shveikin AO, Grinevich VN, Demidova IA. Current approaches to the diagnosis and treatment of gastrointestinal stromal tumors. P.A. Herzen Journal of Oncology. 2013;2(3):82‑87. (In Russ.)

МСФ на ЯМ
Close metadata

Gastrointestinal stromal tumors are the most common mesenchymal sarcomas of the gastrointestinal tract. In 1998 they were identified as an individual nosological entity after determining the pathogenetic mechanisms underlying their occurrence. The given literature review describes present views on the specific features of the pathogenesis, clinical picture, diagnosis, and treatment of these tumors.

Keywords:

gastrointestinal stromal tumors
imanitib mesylate

Authors:

Zabaznyĭ N.P.

Moskovskaia gorodskaia onkologicheskaia bol'nitsa #62

Shveikin A.O.

Moscow City Cancer Hospital No. 62 of Moscow Healthcare Department, Moscow, Russia

Grinevich V.N.

GBUZ "Moskovskaia gorodskaia onkologicheskaia bol'nitsa #62"

Demidova I.A.

FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN", Moskva;
FGBU "Moskovskiĭ NII pediatrii i detskoĭ khirurgii Minzdrava Rossii", Moskva;
Moskovskiĭ gorodskoĭ psikhologo-pedagogicheskiĭ universitet, Moskva

List of references:

  1. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279 (5350): 577-80.
  2. Miettinen M., Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin. Diagn. Pathol. 2006; 23: 70-83.
  3. Miettinen M., Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med. 2006; 130: 1466-78.
  4. Nilsson B., Bümming P., Meis-Kindblom J.M., Odén A., Dortok A., Gustavsson B. et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer. 2005; 103: 821-9.
  5. Gastrointestinal'nye stromal'nye opukholi (diagnostika, lechenie). Prakticheskie rekomendatsii. M.; 2008. 53 s.
  6. Miettinen M., Lasota J., Sobin L.H. Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am. J. Surg. Pathol. 2005; 29: 1373-81.
  7. Prakash S., Sarran L., Socci N., DeMatteo R.P., Eisenstat J., Greco A.M. et al. Gastrointestinal stromal tumors in children and young adults: A clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J. Pediatr. Hematol. Oncol. 2005; 27: 179-87.
  8. Miettinen M., Sarlomo-Rikala M., Sobin L.H., Lasota J. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am. J. Surg. Pathol. 2000; 24: 211-22.
  9. Miettinen M., Sobin L.H. Gastrointestinal stromal tumors in the appendix: A clinicopathologic and immunohistochemical study of four cases. Am. J. Surg. Pathol. 2001; 25: 1433-7.
  10. Miettinen M., Monihan J.M., Sarlomo-Rikala M., Kovatich A.J., Carr N.J., Emory T.S. et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: Clinicopathologic and immunohistochemical study of 26 cases. Am. J. Surg. Pathol. 1999; 23: 1109-18.
  11. Kindblom L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am. J. Pathol. 1998; 152 (5): 1259-69.
  12. Maeda H., Yamagata A., Nishikawa S., Yoshinaga K., Kobayashi S., Nishi K. et al. Requirement of c-kit for development of intestinal pacemaker system. Development. 1992; 116: 369-75.
  13. Takayama I., Horiguchi K., Daigo Y., Mine T., Fujino M.A., Ohno S. The interstitial cells of Cajal and a gastroenteric pacemaker system. Arch. Histol. Cytol. 2002; 65: 1-26.
  14. Corless C.L., Fletcher J.A., Heinrich M.C. Biology of gastrointestinal stromal tumors. J. Clin. Oncol. 2004; 22: 3813-3825.
  15. Kitamura Y., Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol. Life Sci. 2004; 61: 2924-31.
  16. Antonescu C.R., Sommer G., Sarran L., Tschernyavsky S.J., Riedel E., Woodruff J.M. et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin. Cancer Res. 2003; 9: 3329-37.
  17. Lasota J., Wozniak A., Sarlomo-Rikala M., Rys J., Kordek R., Nassar A. et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases. Am. J. Pathol. 2000; 157: 1091-5.
  18. Lux M.L., Rubin B.P., Biase T.L., Chen C.J., Maclure T., Demetri G. et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. 2000; 156: 791-5.
  19. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P. et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 2005; 23: 5357-64.
  20. Lasota J., Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin. Diagn. Pathol. 2006; 23: 91-102.
  21. Lasota J., Dansonka-Mieszkowska A., Sobin L.H., Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest. 2004; 84: 874-83.
  22. Medeiros F., Corless C.L., Duensing A., Hornick J.L., Oliveira A.M., Heinrich M.C. et al. KIT-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications. Am. J. Surg. Pathol. 2004; 28: 889-94.
  23. Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J. et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 2006; 24: 4764-74.
  24. Assämäki R., Sarlomo-Rikala M., Lopez-Guerrero J.A., Lasota J., Andersson L.C., Llombart-Bosch A. et al. Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2007; 46: 564-76.
  25. Lasota J., Wozniak A., Kopczynski J., Dansonka-Mieszkowska A., Wasag B., Mitsuhashi T. et al. Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): A study on 50 cases. Lab. Invest. 2005; 85: 237-47.
  26. Kim H.C., Lee J.M., Choi S.H., Kim K.W., Kim S.H., Lee J.Y. et al. Imaging of gastrointestinal stromal tumors. J. Comput. Assist. Tomogr. 2004; 28: 596-604.
  27. Gomes A.L., Bardales R.H., Milanezi F., Reis R.M., Schmitt F. Molecular analysis of c-kit and PDGFRA in GISTs diagnosed by EUS. Am. J. Clin. Pathol. 2007; 127: 89-96.
  28. Trent J.C., Benjamin R.S. New developments in gastrointestinal stromal tumor. Curr. Opin. Oncol. 2006; 18: 386-395.
  29. Carney J.A. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin. Proc. 1999; 74: 543-52.
  30. Hartmann K., Wardelmann E., Ma Y., Merkelbach-Bruse S., Preussner L.M., Woolery C. et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005; 129: 1042-6.
  31. Miettinen M., Kopczynski J., Makhlouf H.R., Sarlomo-Rikala M., Gyorffy H., Burke A. et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am. J. Surg. Pathol. 2003; 27: 625-41.
  32. Miettinen M., Fetsch J.F., Sobin L.H., Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. 2006; 30: 90-6.
  33. Andersson J., Sihto H., Meis-Kindblom J.M., Joensuu H., Nupponen N., Kindblom L.G. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am. J. Surg. Pathol. 2005; 29: 1170-6.
  34. Takazawa Y., Sakurai S., Sakuma Y., Ikeda T., Yamaguchi J., Hashizume Y. et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am. J. Surg. Pathol. 2005; 29: 755-63.
  35. Carney J.A., Stratakis C.A. Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad. Am. J. Med. Genet. 2002; 108: 132-9.
  36. Isozaki K., Terris B., Belghiti J., Schiffmann S., Hirota S., Vanderwinden J.M. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am. J. Pathol. 2000; 157: 1581-5.
  37. Li F.P., Fletcher J.A., Heinrich M.C., Garber J.E., Sallan S.E., Curiel-Lewandrowski C. et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J. Clin. Oncol. 2005; 23 (12): 2735-43.
  38. Chen H., Hirota S., Isozaki K., Sun H., Ohashi A., Kinoshita K. et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut. 2002; 51: 793-6.
  39. Anurova O.A., Snigur P.V., Filippova N.A., Sel'chuk V.Yu. Morfologicheskaya kharakteristika stromal'nykh opukholei zheludochno-kishechnogo trakta. Arkhiv patologii. 2006; 68 (1): 10-3.
  40. Miettinen M., Virolainen M., Maarit-Sarlomo-Rikala. Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am. J. Surg. Pathol. 1995; 19 (2): 207-16.
  41. van de Rijn M., Hendrickson M.R., Rouse R.V. CD34 expression by gastrointestinal tract stromal tumors. Hum. Pathol. 1994; 25: 766-71.
  42. Blay P., Astudillo A., Buesa J.M., Campo E., Abad M., García-García J. et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin. Cancer Res. 2004; 10: 4089-95.
  43. Duensing A., Joseph N.E., Medeiros F., Smith F., Hornick J.L., Heinrich M.C. et al. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004; 64: 5127-31.
  44. Espinosa I., Lee C.H., Kim M.K., Rouse B.T., Subramanian S., Montgomery K. et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am. J. Surg. Pathol. 2008; 32: 210-8.
  45. Pauwels P., Debiec-Rychter M., Stul M., De Wever I., Van Oosterom A.T., Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: A potential diagnostic pitfall. Histopathology. 2005; 47 (1): 41-7.
  46. Miettinen M., Makhlouf H., Sobin L.H., Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am. J. Surg. Pathol. 2006; 30: 477-89.
  47. Sarlomo-Rikala M., Tsujimura T., Lendahl U., Miettinen M. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS. 2002; 110: 499-507.
  48. Rutkowski P., Bylina E., Wozniak A., Nowecki Z.I., Osuch C., Matlok M. et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur. J. Surg. Oncol. 2011; 37 (10): 890-6.
  49. Gold J.S., Gonen M., Gutierrez A., Broto J.M., García-del-Muro X., Smyrk T.C. et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009; 10: 1045-52.
  50. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum. Pathol. 2008; 39 (10): 1411-9.
  51. Gouveia A.M., Pimenta A.P., Capelinha A.F., de la Cruz D., Silva P., Lopes J.M. Surgical margin status and prognosis of gastrointestinal stromal tumor. World J. Surg. 2008; 32: 2375-82.
  52. Hohenberger P., Ronellenfitsch U., Oladeji O., Pink D., Ströbel P., Wardelmann E. et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br. J. Surg. 2010; 97: 1854-59.
  53. Reichardt P., Blay J.Y., Boukovinas I., Brodowicz T., Broto J.M., Casali P.G. et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann. Oncol. 2012; 23(11): 2776-81.
  54. Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T. et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer. 2006; 42(8): 1093-103.
  55. Appelman H., Helwig E.B. Cellular leiomyomas of the stomach in 49 patients. Arch. Pathol. Lab. Med. 1977; 101: 373-377.
  56. Yantiss R.K., Spiro I.J., Compton C.C., Rosenberg A.E. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: A clinically important differential diagnosis. Am. J. Surg. Pathol. 2000; 24: 947-57.
  57. Bhattacharya B., Dilworth H.P., Iacobuzio-Donahue C., Ricci F., Weber K., Furlong M.A. et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am. J. Surg. Pathol. 2005; 29: 653-9.
  58. Lawrence B., Perez-Atayde A., Hibbard M.K., Rubin B.P., Dal Cin P., Pinkus J.L. et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am. J. Pathol. 2000; 157: 377-84.
  59. Vashakmadze L.A., Khomyakov V.M., Kolobaev I.V. Sovremennye podkhody k lecheniyu bol'nykh stromal'nymi opukholyami zheludochno-kishechnogo trakta. Sovremennaya onkologiya. 2011; 1: 1-4.
  60. Seryakov A.P. Gastrointestinal'nye stromal'nye opukholi. Rossiiskii zhurnal gastroenterologii, gepatologii i koloproktologii. 2010; 20 (4): 49-57.
  61. The ESMO / European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23 (7): 49-55.
  62. Dematteo R.P., Ballman K.V., Antonescu C.R. Maki R.G., Pisters P.W., Demetri G.D. et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 1097-104.
  63. Joensuu H., Eriksson M., Hatrmann J., Sundby Hall K., Schutte J., Reichardt A. et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). In: 47th Annual Meeting of the American Society of Clinical Oncology. June 5, 2011: abstr. No. LBA1.
  64. Nunobe S., Sano T., Shimada K., Sakamoto Y., Kosuge T. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn. J. Clin. Oncol. 2005; 35: 338-41.
  65. Demetri G.D., Benjamin R.S., Blanke C.D., Blay J.Y., Casali P., Choi H. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J. Natl. Compr. Canc. Netw. 2007; 5 (Suppl. 2): 1-29.
  66. von Mehren M., Benjamin R.S., Bui M.M., Casper E.S., Conrad E.U. 3rd, DeLaney T.F. et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 2012, 10 (8): 951-60.
  67. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg. 2000; 231: 51-8.
  68. Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 2008; 26: 620-5.
  69. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S. et al. Phase III randomized, Intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 2008; 26: 626-32.
  70. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364: 1127-34.
  71. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J. Clin. Oncol. 2010; 28: 1247-53.
  72. Eisenberg B.L., Harris J., Blanke C.D., Demetri G.D., Heinrich M.C., Watson J.C. et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol. 2009; 99: 42-7.
  73. Wang D., Zhang Q., Blanke C.D., Demetri G.D., Heinrich M.C., Watson J.C. et al. Phase II Trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann. Surg. Oncol. 2012; 19(4): 1074-80.
  74. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet. 2006; 368: 1329-38.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.